Inhibition of MCP-1 mRNA expression by propylene glycol mannate sulfate in hyperlipidemic rat aorta.
- Author:
Yan GAO
1
;
Wen-gong YU
;
Feng HAN
;
Xin-zhi LU
;
Qian-hong GONG
;
Hua-shi GUAN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Aorta, Thoracic; drug effects; metabolism; Chemokine CCL2; biosynthesis; genetics; Gene Expression; drug effects; Hyperlipidemias; blood; pathology; Hypolipidemic Agents; pharmacology; Male; Malondialdehyde; blood; metabolism; Propylene Glycols; pharmacology; RNA, Messenger; biosynthesis; drug effects; Random Allocation; Rats; Rats, Wistar; Superoxide Dismutase; blood; metabolism
- From: Acta Pharmaceutica Sinica 2003;38(8):582-585
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo study the effects of prophylene glycol mannate sulfate (PGMS) on monocyte chemoattractant protein-1 (MCP-1) mRNA expression in hyperlipidemic rat aorta and to clarify the molecular mechanism of PGMS for the prevention of atherosclerosis.
METHODSPGMS (37.8 and 75.6 mg.kg-1.d-1, ig) or PGMS (37.8 and 75.6 mg.kg-1.d-1, ig) combined with diethyldithiocarbamate (DDC, an inhibitor of SOD, 200 mg.kg-1 every three days, i.p.) were given to hyperlipidemic rats for three weeks. The MDA content and SOD activity were determined after 12 h of starvation, and MCP-1 mRNA expression in aorta was detected by reverse transcription-polymerase chain reaction (RT-PCR).
RESULTSThere was significant decrease (29.46% or 58.40)% of MCP-1 mRNA expression in aortic after the therapy. The SOD activity increased markedly and the MDA content decreased at the same time. After treatment with DDC, the SOD activity was inhibited and the MDA content increased, but with no significant effect on MCP-1 mRNA expression.
CONCLUSIONPGMS inhibited MCP-1 mRNA expression with no relation to its effect on decreasing MDA content.
